Cargando…
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
Background: Ovarian cancer is the most lethal female genital malignancy. Although cisplatin is the first-line chemotherapy to treat ovarian cancer patients along with debulking surgeries, its efficacy is limited due to the high incidence of cisplatin resistance. ATP citrate lyase (ACLY) has been sho...
Autores principales: | Wei, Xuan, Shi, Juanjuan, Lin, Qianhan, Ma, Xiaoxue, Pang, Yingxin, Mao, Hongluan, Li, Rui, Lu, Wei, Wang, Yu, Liu, Peishu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011496/ https://www.ncbi.nlm.nih.gov/pubmed/33816292 http://dx.doi.org/10.3389/fonc.2021.642229 |
Ejemplares similares
-
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway
por: Wei, Xuan, et al.
Publicado: (2021) -
GABPA Expression in Endometrial Carcinoma: A Prognostic Marker
por: Ma, Xiaoxue, et al.
Publicado: (2021) -
Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019) -
MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP
por: Pang, Yingxin, et al.
Publicado: (2014) -
Overexpression of Nucleolin is a Potential Prognostic Marker in Endometrial Carcinoma
por: Lin, Qianhan, et al.
Publicado: (2021)